Comstock (NYSE:LODE – Get Rating) and Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) are both small-cap basic materials companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.
This table compares Comstock and Cyclo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Comstock and Cyclo Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cyclo Therapeutics||$1.59 million||6.61||-$14.29 million||($1.58)||-0.78|
Risk & Volatility
Comstock has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.5, meaning that its stock price is 150% less volatile than the S&P 500.
Institutional & Insider Ownership
6.0% of Comstock shares are held by institutional investors. Comparatively, 4.8% of Cyclo Therapeutics shares are held by institutional investors. 16.4% of Comstock shares are held by insiders. Comparatively, 12.0% of Cyclo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of current ratings for Comstock and Cyclo Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Comstock beats Cyclo Therapeutics on 8 of the 11 factors compared between the two stocks.
Comstock Inc. engages in the exploration, development, and production of mineral properties in Nevada. The company explores for gold, silver, lithium, nickel, cobalt, and mercury ores. It operates in two segments, Mining and Real Estate. The Mining segment owns and controls approximately 9,358 acres of mining claims and parcels, including approximately 2,396 acres of patented claims and surface parcels; and approximately 6,962 acres of unpatented mining claims in the Comstock and Silver City districts, as well as focuses on exploring and developing properties in the Lucerne and Dayton resource areas; and Occidental and Gold Hill mineral properties. The Real Estate segment comprises land and real estate rental properties, as well as the Gold Hill Hotel and Daney Ranch properties. It has collaboration agreements with Oro Industries Inc. and Mercury Clean Up, LLC for the manufacture and deployment of mercury remediation systems with proprietary mechanical, hydro, electro-chemical, and oxidation processes to reclaim and remediate mercury from soils, waste, and tailings. The company was formerly known as Comstock Mining Inc. and changed its name to Comstock Inc. in May 2022. Comstock Inc. was incorporated in 2008 and is based in Virginia City, Nevada.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Receive News & Ratings for Comstock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comstock and related companies with MarketBeat.com's FREE daily email newsletter.